Triple threat before surgery: could this combo shrink lung tumors better?
NCT ID NCT06877299
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial is testing whether giving a combination of low-dose radiation, stereotactic body radiotherapy (SBRT), the immunotherapy drug tislelizumab, and standard chemotherapy before surgery can improve outcomes for people with stage II to III non-small cell lung cancer. The study will enroll 30 participants whose tumors are considered removable. The main goal is to see how many patients have no cancer cells left in their surgical samples (pathologic complete response).
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Tislelizumab (immunotherapy) plus platinum-based chemotherapy, combined with low-dose radiation and stereotactic body radiotherapy (SBRT)
- What this could lead to
- If successful, this approach could shrink tumors before surgery, potentially improving survival and reducing recurrence in people with resectable non-small cell lung cancer.
- What could go wrong
- This is a small, early-phase (phase 2) study with only 30 participants, so results may not apply to everyone. The combination of radiation, immunotherapy, and chemotherapy also carries risks of serious side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
West China Hospital of Sichuan University
RECRUITINGChengdu, China, 610041, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple CT scan catch lung cancer earlier in kuwait?
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Could a bronchial wash detect lung cancer mutations faster?